TY - JOUR
T1 - Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C
T2 - a pilot study
AU - Andersen, E S
AU - Rødgaard-Hansen, Sidsel
AU - Moessner, B
AU - Christensen, P B
AU - Møller, H J
AU - Weis, Nina
N1 - Authors
E. S. Andersen (1) (2)
S. Rødgaard-Hansen (3)
B. Moessner (4)
P. B. Christensen (4)
H. J. Møller [email protected] (3)
Nina Weis (1) (5)
Author Affiliations
1. Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Copenhagen, Denmark
2. Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
3. Department of Clinical Biochemistry, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus C, Denmark
4. Department of Infectious Diseases, Odense University Hospital, Odense, Denmark
5. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
PY - 2014/1
Y1 - 2014/1
N2 - Macrophages regulate the fibrotic process in chronic liver disease. The aim of the present pilot study was to evaluate two new macrophage-specific serum biomarkers [soluble CD163 (sCD163) and soluble mannose receptor (sMR, sCD206)] as potential fibrosis markers in patients chronically infected with hepatitis C virus (HCV). Forty patients with chronic hepatitis C were included from two hospital clinics. On the day of inclusion, transient elastography (TE) was performed to assess the fibrosis stage, and blood samples were collected for the measurement of sCD163 and sMR. The plasma concentrations of both biomarkers were significantly higher in patients infected with HCV and with cirrhosis compared to those with no/mild liver fibrosis (5.77 mg/l vs. 2.49 mg/l and 0.44 mg/l vs. 0.30 mg/l for sCD163 and sMR, respectively). The best separation between groups was obtained by sCD163 [area under the receiver operating characteristic curve (AUC) 0.89 (95 % confidence interval [CI] 0.79-0.99)] as compared to sMR [AUC 0.75 (95 % CI 0.61-0.90)]. sCD163 and sMR correlated significantly (r (2) = 0.53, p
AB - Macrophages regulate the fibrotic process in chronic liver disease. The aim of the present pilot study was to evaluate two new macrophage-specific serum biomarkers [soluble CD163 (sCD163) and soluble mannose receptor (sMR, sCD206)] as potential fibrosis markers in patients chronically infected with hepatitis C virus (HCV). Forty patients with chronic hepatitis C were included from two hospital clinics. On the day of inclusion, transient elastography (TE) was performed to assess the fibrosis stage, and blood samples were collected for the measurement of sCD163 and sMR. The plasma concentrations of both biomarkers were significantly higher in patients infected with HCV and with cirrhosis compared to those with no/mild liver fibrosis (5.77 mg/l vs. 2.49 mg/l and 0.44 mg/l vs. 0.30 mg/l for sCD163 and sMR, respectively). The best separation between groups was obtained by sCD163 [area under the receiver operating characteristic curve (AUC) 0.89 (95 % confidence interval [CI] 0.79-0.99)] as compared to sMR [AUC 0.75 (95 % CI 0.61-0.90)]. sCD163 and sMR correlated significantly (r (2) = 0.53, p
U2 - 10.1007/s10096-013-1936-3
DO - 10.1007/s10096-013-1936-3
M3 - Journal article
C2 - 24424890
SN - 0934-9723
VL - 33
SP - 117
EP - 122
JO - European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
JF - European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
IS - 1
ER -